Joseph Radzwilka, DO
General Practice · West Pittston, PANPI 1871520957
Payments from drug & device makers
Across 163 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$424
- Amgen$359
- AbbVie$252
- Lilly USA, LLC$239
- GSK$186
- AstraZeneca$129
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,600100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $424 |
| Amgen | 22 | $359 |
| AbbVie | 12 | $252 |
| Lilly USA, LLC | 15 | $239 |
| GSK | 13 | $186 |
| AstraZeneca(2 entities) | 9 | $129 |
| Novartis | 8 | $126 |
| Bayer | 6 | $107 |
| E.r. Squibb & Sons, L.L.C. | 7 | $106 |
| Johnson & Johnson | 4 | $63 |
| Biohaven Pharmaceuticals, Inc. | 3 | $52 |
| Avanir Pharmaceuticals, Inc. | 3 | $47 |
| Radius Health, Inc. | 3 | $47 |
| Abbott | 3 | $47 |
| Almatica Pharma LLC | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Pfizer | 2 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Sanofi Pasteur Inc. | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Merck | 2 | $26 |
| Astellas Pharma US Inc | 2 | $25 |
| Shield Therapeutics Inc | 1 | $24 |
| Boston Scientific | 2 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Exact Sciences | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
| Philips North America LLC | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
How this compares
$2,600 in reported general payments places this provider in the 95th percentile of 3,208 general practice providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 218 | $118,771 |
| NuplazidPimavanserin Tartrate | 14 | $70,398 |
| JardianceEmpagliflozin | 24 | $16,305 |
| XareltoRivaroxaban | 25 | $14,783 |
| MyrbetriqMirabegron | 28 | $14,468 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,910 |
| TrulicityDulaglutide | 11 | $11,248 |
| JanuviaSitagliptin Phosphate | 17 | $10,481 |
| Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc | 96 | $9,635 |
| TrintellixVortioxetine Hydrobromide | 12 | $7,018 |
| TradjentaLinagliptin | 13 | $7,018 |
| Atorvastatin Calcium | 576 | $6,705 |
| CequaCyclosporine | 11 | $5,709 |
| Memantine Hcl | 76 | $4,648 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $4,373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $35 | $118,771218 claims |
| Boehringer IngelheimJardiance, Tradjenta | $11 | $23,32337 claims |
| Johnson & JohnsonXarelto | $63 | $14,78325 claims |
| Astellas Pharma US IncMyrbetriq | $25 | $14,46828 claims |
| GSKTrelegy Ellipta | $186 | $13,91020 claims |
| Lilly USA, LLCTrulicity | $239 | $11,24811 claims |
| MerckJanuvia | $26 | $10,48117 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $13 | $7,01812 claims |
| AstraZenecaBrilinta | $129 | $3,21427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,208 general practice providers in Pennsylvania.
Other general practice in West Pittston
- Corey AnolikPhiladelphia$2.1M
- Richard NagelbergPlymouth Meeting$1.4M
- Alan AtlasPhiladelphia$486K
- Susan McMahonPittsburgh$364K
- Yooson KimMorgantown$316K
- Carl MedgausMonroeville$192K
- Michele ColumboBryn Mawr$126K
- Michael WollockArdmore$113K
- Barry BartusiakWashington$104K
- Marc ManosPhiladelphia$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.